regulators authorized Covid booster shots of Pfizer and BioNTech's vaccine to a wide array of Americans, including the elderly, adults with underlying medical conditions and those who work or live in high-risk settings like health and grocery workers.
moves closer to clearing Moderna and J&J Covid booster shots this week .
The FDA advisory group is scheduled Thursday to discuss data on the safety and effectiveness of a Moderna booster shot in adults.On Friday, the committee is expected to debate J&J booster shots for adults.
Last month, Moderna said a third shot at half the dosage used for the first two jabs was safe and produced a stronger immune response than what was seen after the second dose in its phase three clinical trial.The FDA could authorize Moderna and J&J booster shots under the same criteria as Pfizer or perhaps change course and broaden the number of Americans eligible to receive extra shots, Baylor said in a phone interview.Committee members will have to debate whether its safe and effective for J&J recipients to get a second dose, Baylor said?"If I were at the FDA in my old position, I probably would not have taken the Moderna to the advisory committee because it's in the same class as Pfizer," he said